{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T01:51:24Z","timestamp":1777945884149,"version":"3.51.4"},"reference-count":31,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T00:00:00Z","timestamp":1773532800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["The Prostate"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>\n                      Further work is needed to improve treatment outcomes for prostate cancer (PCa), with the repurposing of the \u03b1\n                      <jats:sub>1<\/jats:sub>\n                      \u2010adrenoreceptor antagonists presenting a potential solution. This feasibility clinical trial presents the first prospective data of the use of an \u03b1\n                      <jats:sub>1<\/jats:sub>\n                      \u2010adrenoreceptor antagonist in men undergoing radiotherapy for PCa.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The study enrolled men planned to receive radiotherapy for PCa. Participants received escalating doses of prazosin administered during radiotherapy. Blood pressure was recorded at each radiotherapy fraction. The primary outcome was treatment protocol feasibility and secondary outcomes were maximum tolerated dose (MTD) of prazosin, safety, and progression\u2010free survival (PFS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten participants were enrolled into the study and all achieved &gt;\u200990% treatment compliance and &gt;\u200980% assessment compliance. One participant and four participants achieved an MTD of 1\u2009mg and 0.5\u2009mg, respectively, and the remaining five participants had an MTD of 0\u2009mg, with the overall protocol defined MTD being 0\u2009mg. There were no Grades 3\/4 adverse events. All treatment\u2010related adverse events (TRAE) were either hypotension or orthostatic hypotension, of the 17 reported TRAEs 16 were asymptomatic. No participants had evidence of disease progression at the 36\u2010week follow\u2010up.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study demonstrated that coadministration of prazosin during radiotherapy is feasible. However, the incidence of hypotension resulted in a protocol\u2010defined MTD (under conservative blood pressure based DLT definition) of 0\u2009mg, although 16 of the 17 reports were asymptomatic. Combined with monitoring used in other studies utilizing prazosin, this suggests that our safety monitoring and dose\u2010limiting toxicity (DLT) definition may have been too strict and did not accurately reflect a clinically relevant MTD. As this study achieved its primary aim and demonstrated the feasibility of the administration of prazosin during radiotherapy, further prospective studies are justified, with greater consideration given to the definition of DLTs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial Registration<\/jats:title>\n                    <jats:p>Australian New Zealand Clinical Trials Registry (381954).<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/pros.70162","type":"journal-article","created":{"date-parts":[[2026,3,15]],"date-time":"2026-03-15T22:09:10Z","timestamp":1773612550000},"page":"891-899","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A Feasibility Study of the Repurposing of Prazosin to Improve Treatment Outcomes in Men Receiving Radiotherapy for Prostate Cancer (MiniRaP\u201000)"],"prefix":"10.1002","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6816-3784","authenticated-orcid":false,"given":"Liam D.","family":"King","sequence":"first","affiliation":[{"name":"School of Pharmacy and Medical Sciences Griffith University Gold Coast Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5494-8751","authenticated-orcid":false,"given":"David","family":"Christie","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Medical Sciences Griffith University Gold Coast Queensland Australia"},{"name":"GenesisCare Gold Coast Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Cehic","sequence":"additional","affiliation":[{"name":"Advara HeartCare Adelaide South Australia Australia"},{"name":"University of Adelaide Adelaide South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Dare","sequence":"additional","affiliation":[{"name":"Ramsay Pharmacy Group Melbourne Victoria Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Russ","family":"Chess\u2010Williams","sequence":"additional","affiliation":[{"name":"Faculty of Health Science and Medicine Bond University Gold Coast Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0082-4216","authenticated-orcid":false,"given":"Donna","family":"Sellers","sequence":"additional","affiliation":[{"name":"Faculty of Health Science and Medicine Bond University Gold Coast Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"McDermott","sequence":"additional","affiliation":[{"name":"Faculty of Health Science and Medicine Bond University Gold Coast Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"McCarthy","sequence":"additional","affiliation":[{"name":"Griffith Health Group Griffith University Gold Coast Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shailendra","family":"Anoopkumar\u2010Dukie","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Medical Sciences Griffith University Gold Coast Queensland Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2026,3,15]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.0228"},{"key":"e_1_2_11_4_1","doi-asserted-by":"crossref","unstructured":"A.Kirtonia K.Gala S. G.Fernandes et al. \u201cRepurposing of Drugs: An Attractive Pharmacological Strategy for Cancer Therapeutics \u201d inSeminars in Cancer Biology(Elsevier 2021).","DOI":"10.1016\/j.semcancer.2020.04.006"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trecan.2017.06.007"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsomega.2c05821"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24044154"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000369"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2020.173831"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23167"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.21313"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1593\/neo.07475"},{"issue":"16","key":"e_1_2_11_13_1","first-page":"4550","article-title":"Suppression of Human Prostate Cancer Cell Growth by Alpha1\u2010Adrenoceptor Antagonists Doxazosin and Terazosin via Induction of Apoptosis","volume":"60","author":"Kyprianou N.","year":"2000","journal-title":"Cancer Research"},{"issue":"3","key":"e_1_2_11_14_1","first-page":"1673","article-title":"Alpha1\u2010Adrenoceptor Antagonists Radiosensitize Prostate Cancer Cells via Apoptosis Induction","volume":"22","author":"Cuellar D. C.","year":"2002","journal-title":"Anticancer Research"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2007.06.043"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/pros.1083"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-65238-z"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2006.04.029"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30456-3"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-009-0174-4"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2019.04.047"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1097-0045(19970215)30:3<202::AID-PROS9>3.0.CO;2-N"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1097\/MJT.0b013e3181a2b1bb"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1111\/add.16484"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1097\/JGP.0b013e3181ab8c61"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/head.14529"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1111\/acer.14989"},{"key":"e_1_2_11_28_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2018.17080913"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20050609"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16081541"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.3109\/02841867609131961"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajh\/hpx158"}],"container-title":["The Prostate"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.70162","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pros.70162","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pros.70162","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T13:50:06Z","timestamp":1777729806000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pros.70162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,15]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/pros.70162"],"URL":"https:\/\/doi.org\/10.1002\/pros.70162","archive":["Portico"],"relation":{},"ISSN":["0270-4137","1097-0045"],"issn-type":[{"value":"0270-4137","type":"print"},{"value":"1097-0045","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,15]]},"assertion":[{"value":"2025-09-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-15","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}